Binge Eating Disorder Protocol

Mental HealthEmerging Evidence

supplements

Primary

Supporting

Grade A

Studies

Primary Stack

Core supplements with strongest evidence

N-Acetyl Cysteine (NAC)B

1200-2400mg daily (divided doses)

Modulates glutamate signaling in reward circuits, reducing compulsive eating behaviors

3 studies120 participants

Supporting Studies (2)

PMID: 25649840 - NAC for eating disorders (2015)PMID: 28107632 - N-acetyl cysteine in binge eating (2017)

Chromium PicolinateB

600-1000mcg daily

Enhances insulin sensitivity and reduces carbohydrate cravings by stabilizing blood sugar

↑Binge-eating↓Blood glucose↓HbA1c↓Weight

4 studies185 participants

Supporting Studies (1)

PMID: 15716712 - Chromium in atypical depression with carbohydrate craving (2005)

Supporting Stack

Additional supplements for enhanced results

Inositol (Myo-inositol)C

12-18g daily (divided doses)

Acts as second messenger in serotonin signaling, improving impulse control and mood

↓Anxiety Symptoms↑Binge-eating↓Depression Symptoms

2 studies48 participants

Supporting Studies (1)

PMID: 11386498 - Inositol in binge eating and bulimia (2001)

5-HTPC

150-300mg daily

Serotonin precursor that enhances satiety signaling and reduces emotional eating

2 studies40 participants

How This Protocol Works

Simple Explanation

Binge eating disorder involves dysregulated reward circuits, impaired impulse control, and often unstable blood sugar that drives cravings. This protocol addresses the neurological and metabolic drivers.

•NAC is emerging as one of the most promising supplements for compulsive behaviors. It modulates glutamate in the nucleus accumbens (reward center), reducing the "urge" component of binge eating. Studies show significant reduction in binge frequency.

•Chromium addresses the metabolic component—many binge episodes are triggered by blood sugar crashes. By improving insulin sensitivity, chromium reduces intense carbohydrate cravings.

•Inositol supports serotonin function, which is often impaired in eating disorders. High doses (12-18g) have shown benefit for OCD-spectrum conditions including binge eating.

•5-HTP directly increases serotonin synthesis, enhancing the "fullness" signal and reducing emotional eating triggers.

Expected timeline: Reduced craving intensity within 2-3 weeks. Decreased binge frequency over 6-8 weeks. Best combined with cognitive behavioral therapy (CBT).

Clinical Perspective

BED pathophysiology involves dysfunction in prefrontal cortex (impulse control), nucleus accumbens (reward processing), and hypothalamic satiety signaling. Glutamate-dopamine imbalance plays a central role.

•NAC (B-grade): Restores glutamate homeostasis via cystine-glutamate antiporter (xCT system). Reduces extrasynaptic glutamate in NAc, decreasing compulsive drive. Meta-analyses show efficacy in impulse control disorders. Dose: 1200mg BID (PMID: 28107632).

•Chromium (B-grade): Enhances insulin receptor sensitivity via increased GLUT4 translocation. Stabilizes glucose fluctuations that trigger binge episodes. Also increases tryptophan transport across BBB, supporting serotonin synthesis. Effective dose: 600-1000mcg/day chromium picolinate (PMID: 15716712).

•Inositol (C-grade): Functions as PI cycle second messenger in 5-HT2 receptor signaling. High doses (12-18g) comparable to SSRIs for OCD-spectrum conditions. Start low (2g) and titrate to avoid GI distress.

•5-HTP (C-grade): Bypasses rate-limiting tryptophan hydroxylase, directly increasing serotonin synthesis. Enhances hypothalamic satiety signaling via 5-HT2C receptors.

Biomarker monitoring: Fasting glucose/insulin (HOMA-IR), urinary 5-HIAA (serotonin metabolite).

Caution: Avoid 5-HTP with SSRIs (serotonin syndrome risk). Monitor chromium with diabetes medications.

View All Protocols